Unicyte Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$66.6M
- Investors
-
1
Unicyte General Information
Description
Operator of a transformative regenerative medicine company intended to advance stem cell technologies into a novel class of human therapeutics. The company has developed a broad preclinical pipeline in key therapeutic areas of human liver stem cells, functional pancreatic islets, and nano-extracellular vesicles, enabling doctors to improve the lives of patients with kidney or liver disease, diabetes, and cancer.
Contact Information
Website
www.unicyte.chCorporate Office
- Aawasserstrasse 2
- Nidwalden
- 6370 Oberdorf
- Switzerland
Corporate Office
- Aawasserstrasse 2
- Nidwalden
- 6370 Oberdorf
- Switzerland
Unicyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 05-Sep-2019 | $66.6M | Completed | Clinical Trials - Phase 2 |
Unicyte Comparisons
Industry
Financing
Details
Unicyte Competitors (3)
One of Unicyte’s 3 competitors is Orbsen Therapeutics, a Private Equity-Backed company based in Galway, Ireland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orbsen Therapeutics | Private Equity-Backed | Galway, Ireland | ||||
| ProKidney | Corporation | Winston-Salem, NC | ||||
| Evox Therapeutics | Venture Capital-Backed | Oxford, United Kingdom |
Unicyte Patents
Unicyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4534649-A1 | A method of qualifying as pharmaceutically active a batch of undifferentiated adult stem cells having the potential to differentiate along the hepatic lineage | Inactive | 03-Oct-2023 | ||
| WO-2025074243-A1 | A method of qualifying as pharmaceutically active a batch of undifferentiated adult stem cells having the potential to differentiate along the hepatic lineage | Inactive | 03-Oct-2023 |
Unicyte Signals
Unicyte Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fresenius Medical Care | Corporation | Minority |
Unicyte FAQs
-
When was Unicyte founded?
Unicyte was founded in 2015.
-
Where is Unicyte headquartered?
Unicyte is headquartered in Oberdorf, Switzerland.
-
What is the size of Unicyte?
Unicyte has 14 total employees.
-
What industry is Unicyte in?
Unicyte’s primary industry is Drug Discovery.
-
Is Unicyte a private or public company?
Unicyte is a Private company.
-
What is Unicyte’s current revenue?
The current revenue for Unicyte is .
-
How much funding has Unicyte raised over time?
Unicyte has raised $66.6M.
-
Who are Unicyte’s investors?
Fresenius Medical Care has invested in Unicyte.
-
Who are Unicyte’s competitors?
Orbsen Therapeutics, ProKidney, and Evox Therapeutics are competitors of Unicyte.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process